Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Morari

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|November 9, 2011
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo studyElisabetta Esposito, Paolo Mariani, Laura Ravani, et al.
Neurobiology of Disease|June 17, 2018
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's diseaseAlessandro Tozzi, Valentina Durante, Guendalina Bastioli, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 16, 2012
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesiasMatteo Marti, Donata Rodi, Qin Li, et al.
Molecular and Cellular Neurosciences|February 14, 2004
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's diseaseEmilia Saulle, Paolo Gubellini, Barbara Picconi, et al.
Biomedicines|June 2, 2021
Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X MouseMaria Regoni, Letizia Zanetti, Stefano Comai, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 30, 2004
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behaviorMatteo Marti, Flora Mela, Carlo Veronesi, et al.
British Journal of Pharmacology|May 16, 2002
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptorGirolamo Calo, Anna Rizzi, Daniela Rizzi, et al.
Journal of Medicinal Chemistry|January 18, 2020
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease ModelsUma Gayathri Kamakolanu, Michael E Meyer, Dennis Yasuda, et al.
British Journal of Pharmacology|November 12, 2021
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l-Dopa-induced dyskinesiaClarissa A Pisanò, Daniela Mercatelli, Martina Mazzocchi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 28, 2017
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight GainAlessandro Rimessi, Chiara Pavan, Elli Ioannidi, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|November 9, 2011
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo studyElisabetta Esposito, Paolo Mariani, Laura Ravani, et al.
Neurobiology of Disease|June 17, 2018
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's diseaseAlessandro Tozzi, Valentina Durante, Guendalina Bastioli, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 16, 2012
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesiasMatteo Marti, Donata Rodi, Qin Li, et al.
Molecular and Cellular Neurosciences|February 14, 2004
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's diseaseEmilia Saulle, Paolo Gubellini, Barbara Picconi, et al.
Biomedicines|June 2, 2021
Early Dysfunction of Substantia Nigra Dopamine Neurons in the ParkinQ311X MouseMaria Regoni, Letizia Zanetti, Stefano Comai, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 30, 2004
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behaviorMatteo Marti, Flora Mela, Carlo Veronesi, et al.
British Journal of Pharmacology|May 16, 2002
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptorGirolamo Calo, Anna Rizzi, Daniela Rizzi, et al.
Journal of Medicinal Chemistry|January 18, 2020
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease ModelsUma Gayathri Kamakolanu, Michael E Meyer, Dennis Yasuda, et al.
British Journal of Pharmacology|November 12, 2021
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for l-Dopa-induced dyskinesiaClarissa A Pisanò, Daniela Mercatelli, Martina Mazzocchi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 28, 2017
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight GainAlessandro Rimessi, Chiara Pavan, Elli Ioannidi, et al.
Pageof 10